11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Padviram

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Emtricitabin

Emtricitabin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

      2 2
      2 2

      Tenofovirdisoproxil

      Tenofovirdisoproxil

      Klass : 2

      Visa all info

      Skriv ut

      Kontakta oss

      1. Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. Am J Reprod Immunol. 2015;73:199-213.

      2. Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. AIDS. 2017;31:213-232.

      3. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis. 2013;57:1773-81.

      4. Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502-7.

      5. The Antiretroviral Pregnancy Registry. Interim report 1 January 1989 through 31 July 2021. The Antiretroviral Pregnancy Registry [www]. [updated 2021-12-31, cited 2022-03-04].

      6. Pan CQ, Dai E, Duan Z, Han G, Zhao W, Wang Y et al. Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China. Gut. 2022;71(4):798-806.

      7. Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C et al. Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. N Engl J Med. 2018;378(10):911-923.

      8. Wang M, Bian Q, Zhu Y, Pang Q, Chang L, Li R et al. Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. Aliment Pharmacol Ther. 2019;49(2):211-217.

      1. Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. Am J Reprod Immunol. 2015;73:199-213.
      2. Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. AIDS. 2017;31:213-232.
      3. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis. 2013;57:1773-81.
      4. Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502-7.
      5. The Antiretroviral Pregnancy Registry. Interim report 1 January 1989 through 31 July 2021. The Antiretroviral Pregnancy Registry [www]. [updated 2021-12-31, cited 2022-03-04].
      6. Pan CQ, Dai E, Duan Z, Han G, Zhao W, Wang Y et al. Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China. Gut. 2022;71(4):798-806.
      7. Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C et al. Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. N Engl J Med. 2018;378(10):911-923.
      8. Wang M, Bian Q, Zhu Y, Pang Q, Chang L, Li R et al. Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. Aliment Pharmacol Ther. 2019;49(2):211-217.
      2 2
      2 2

      Efavirenz

      Efavirenz

      Klass : 2

      Visa all info

      Skriv ut

      Kontakta oss

      1. Williams PL, Yildirim C, Chadwick EG, Van Dyke RB, Smith R, Correia KF et al. Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study. Lancet HIV. 2020;7(1):e49-e58.

      2. Martinez de Tejada B, European Pregnancy and Paediatric HIV Cohort Collaboration Study Group. Birth Defects After Exposure to Efavirenz-Based Antiretroviral Therapy at Conception/First Trimester of Pregnancy: A Multicohort Analysis. J Acquir Immune Defic Syndr. 2019;80(3):316-324.

      3. Knapp KM, Brogly SB, Muenz DG, Spiegel HM, Conway DH, Scott GB et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J. 2012;31:164-70.

      4. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011;25:2301-4.

      5. Ford N, Mofenson L, Kranzer K, Medu L, Frigati L, Mills EJ, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010;24:1461-70.

      6. Brogly SB, Abzug MJ, Watts DH, Cunningham CK, Williams PL, Oleske J et al. Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J. 2010;29:721-7.

      7. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS. 2009;23:519-24.

      8. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. New Engl J Med 2002;346:1863-70.

      1. Williams PL, Yildirim C, Chadwick EG, Van Dyke RB, Smith R, Correia KF et al. Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study. Lancet HIV. 2020;7(1):e49-e58.
      2. Martinez de Tejada B, European Pregnancy and Paediatric HIV Cohort Collaboration Study Group. Birth Defects After Exposure to Efavirenz-Based Antiretroviral Therapy at Conception/First Trimester of Pregnancy: A Multicohort Analysis. J Acquir Immune Defic Syndr. 2019;80(3):316-324.
      3. Knapp KM, Brogly SB, Muenz DG, Spiegel HM, Conway DH, Scott GB et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J. 2012;31:164-70.
      4. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011;25:2301-4.
      5. Ford N, Mofenson L, Kranzer K, Medu L, Frigati L, Mills EJ, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010;24:1461-70.
      6. Brogly SB, Abzug MJ, Watts DH, Cunningham CK, Williams PL, Oleske J et al. Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J. 2010;29:721-7.
      7. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS. 2009;23:519-24.
      8. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. New Engl J Med 2002;346:1863-70.